Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cypress Bioscience has closed the acquisition of Proprius Pharmaceutical with an upfront payment of approximately $37.5 million in cash
Subscribe to our email newsletter
Cypress will also get an additional $37.5 million in potential milestone-related payments associated with the development of Proprius’s therapeutic candidates.
The acquisition brings together Cypress’s drug development expertise, commercial resources and lead pharmaceutical candidate, milnacipran, which is currently under FDA review for the treatment of fibromyalgia, and Proprius’s unique portfolio of proprietary, high-value personalized medicine laboratory services and therapeutic product candidates.